CH526959A - Verfahren zur Herstellung eines avirulenten Antitumorpräparates aus Streptococcus hemolyticus - Google Patents
Verfahren zur Herstellung eines avirulenten Antitumorpräparates aus Streptococcus hemolyticusInfo
- Publication number
- CH526959A CH526959A CH331067A CH331067A CH526959A CH 526959 A CH526959 A CH 526959A CH 331067 A CH331067 A CH 331067A CH 331067 A CH331067 A CH 331067A CH 526959 A CH526959 A CH 526959A
- Authority
- CH
- Switzerland
- Prior art keywords
- suspension
- minutes
- penicillin
- bbm
- streptococcus hemolyticus
- Prior art date
Links
- 241000193996 Streptococcus pyogenes Species 0.000 title claims abstract description 23
- 229940049954 penicillin Drugs 0.000 claims abstract description 44
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims abstract description 43
- 229930182555 Penicillin Natural products 0.000 claims abstract description 41
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 12
- 238000010438 heat treatment Methods 0.000 claims abstract description 10
- 230000002949 hemolytic effect Effects 0.000 claims abstract description 8
- 239000000725 suspension Substances 0.000 claims description 61
- 238000002360 preparation method Methods 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 23
- 239000002609 medium Substances 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 18
- 239000002504 physiological saline solution Substances 0.000 claims description 17
- 244000005700 microbiome Species 0.000 claims description 10
- 238000011534 incubation Methods 0.000 claims description 7
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000013372 meat Nutrition 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 102000006382 Ribonucleases Human genes 0.000 claims description 2
- 108010083644 Ribonucleases Proteins 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 229920002477 rna polymer Polymers 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 2
- 239000008103 glucose Substances 0.000 abstract description 2
- 230000001717 pathogenic effect Effects 0.000 abstract description 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000699670 Mus sp. Species 0.000 description 23
- 210000004027 cell Anatomy 0.000 description 21
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 18
- 239000000571 coke Substances 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000006285 cell suspension Substances 0.000 description 10
- 108010075242 streptolysin S Proteins 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 9
- 229960003920 cocaine Drugs 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000001727 in vivo Methods 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000001018 virulence Effects 0.000 description 6
- 238000009631 Broth culture Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- FCPVYOBCFFNJFS-UHFFFAOYSA-N sodium;3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound [Na+].O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 FCPVYOBCFFNJFS-UHFFFAOYSA-N 0.000 description 5
- 239000012530 fluid Substances 0.000 description 4
- 238000011533 pre-incubation Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 241001478240 Coccus Species 0.000 description 2
- 239000007836 KH2PO4 Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
- 235000019796 monopotassium phosphate Nutrition 0.000 description 2
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000003468 Ehrlich Tumor Carcinoma Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010048960 Streptococcal sepsis Diseases 0.000 description 1
- 108010011834 Streptolysins Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- IYNDLOXRXUOGIU-LQDWTQKMSA-M benzylpenicillin potassium Chemical compound [K+].N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 IYNDLOXRXUOGIU-LQDWTQKMSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000012898 sample dilution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/885—Streptococcus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Tropical Medicine & Parasitology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Soil Working Implements (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP1378466 | 1966-03-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH526959A true CH526959A (de) | 1972-08-31 |
Family
ID=11842860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH331067A CH526959A (de) | 1966-03-08 | 1967-03-07 | Verfahren zur Herstellung eines avirulenten Antitumorpräparates aus Streptococcus hemolyticus |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US3477914A (en:Method) |
| BE (1) | BE695122A (en:Method) |
| CA (1) | CA950847A (en:Method) |
| CH (1) | CH526959A (en:Method) |
| CS (1) | CS150186B2 (en:Method) |
| DE (1) | DE1617397C3 (en:Method) |
| DK (1) | DK115652B (en:Method) |
| ES (1) | ES337684A1 (en:Method) |
| FR (1) | FR6516M (en:Method) |
| GB (1) | GB1132676A (en:Method) |
| NL (1) | NL6703623A (en:Method) |
| NO (1) | NO121972B (en:Method) |
| SE (1) | SE348943B (en:Method) |
| SU (1) | SU520055A3 (en:Method) |
| YU (1) | YU33209B (en:Method) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3627644A (en) * | 1968-03-01 | 1971-12-14 | Hajime Okamoto | Process for the cultivation of hemolytic streptococci |
| JPS496096B1 (en:Method) * | 1970-09-30 | 1974-02-12 | ||
| JPS54157815A (en) * | 1978-05-29 | 1979-12-13 | Chugai Pharmaceut Co Ltd | Anti-tumor substance and its preparation |
| JPS557014A (en) * | 1978-06-29 | 1980-01-18 | Chugai Pharmaceut Co Ltd | Antitumor agent and its preparation |
| JPS5679622A (en) * | 1979-12-04 | 1981-06-30 | Kanebo Ltd | Antitumor pharmaceutical |
| GB2079785B (en) * | 1980-04-14 | 1984-10-03 | Kanebo Ltd | Process for cultivation of hemolytic streptococcus pyogenes |
| FR2481314A1 (fr) * | 1980-04-25 | 1981-10-30 | Kanebo Ltd | Procede de culture du micro-organisme streptococcus pyogenes hemolytique |
| US4401653A (en) * | 1981-03-09 | 1983-08-30 | Ayerst, Mckenna & Harrison Inc. | Combination of rapamycin and picibanil for the treatment of tumors |
| AU5359186A (en) * | 1985-01-25 | 1986-08-13 | Population Council, Inc., The | Method & product for enhancing circulating antibody response |
| CN120435302A (zh) | 2023-01-09 | 2025-08-05 | 普罗塔拉治疗公司 | 化脓性链球菌非活细胞与免疫检查点抑制剂联合治疗三阴性乳腺癌和非肌层浸润性膀胱癌 |
-
1967
- 1967-03-03 GB GB10290/67A patent/GB1132676A/en not_active Expired
- 1967-03-06 DE DE1617397A patent/DE1617397C3/de not_active Expired
- 1967-03-06 US US620661A patent/US3477914A/en not_active Expired - Lifetime
- 1967-03-07 DK DK117967AA patent/DK115652B/da not_active IP Right Cessation
- 1967-03-07 FR FR97672A patent/FR6516M/fr not_active Expired
- 1967-03-07 BE BE695122D patent/BE695122A/xx not_active IP Right Cessation
- 1967-03-07 CH CH331067A patent/CH526959A/de not_active IP Right Cessation
- 1967-03-07 NO NO167165A patent/NO121972B/no unknown
- 1967-03-07 SU SU1139070A patent/SU520055A3/ru active
- 1967-03-07 ES ES337684A patent/ES337684A1/es not_active Expired
- 1967-03-08 CA CA984,715,A patent/CA950847A/en not_active Expired
- 1967-03-08 NL NL6703623A patent/NL6703623A/xx unknown
- 1967-03-08 YU YU0452/67A patent/YU33209B/xx unknown
- 1967-03-08 SE SE03170/67A patent/SE348943B/xx unknown
- 1967-03-08 CS CS1700A patent/CS150186B2/cs unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SE348943B (en:Method) | 1972-09-18 |
| CA950847A (en) | 1974-07-09 |
| SU520055A3 (ru) | 1976-06-30 |
| DE1617397B2 (de) | 1979-05-03 |
| NL6703623A (en:Method) | 1967-09-11 |
| GB1132676A (en) | 1968-11-06 |
| DE1617397A1 (de) | 1971-03-18 |
| BE695122A (en:Method) | 1967-08-14 |
| YU33209B (en) | 1976-06-30 |
| ES337684A1 (es) | 1968-03-01 |
| DE1617397C3 (de) | 1980-01-03 |
| US3477914A (en) | 1969-11-11 |
| DK115652B (da) | 1969-10-27 |
| FR6516M (en:Method) | 1968-12-09 |
| NO121972B (en:Method) | 1971-05-03 |
| YU45267A (en) | 1975-12-31 |
| CS150186B2 (en:Method) | 1973-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2908241C2 (de) | Die tumorspezifische Immunität vergrößernder Bakterienzellenextrakt und Verfahren zu seiner Herstellung | |
| DE69019640T2 (de) | Verfahren zur herstellung von beta-1,3-glucan in algen. | |
| CH316291A (de) | Verfahren zur Herstellung von Tetracyclin | |
| CH687233A5 (de) | Neue abgeschwaechte Pseudomonas aeruginosa Staemme. | |
| CH526959A (de) | Verfahren zur Herstellung eines avirulenten Antitumorpräparates aus Streptococcus hemolyticus | |
| DE2900591A1 (de) | Antibiotica, ein verfahren zu ihrer herstellung sowie ihre verwendung als pflanzenschutzmittel | |
| DE3541044A1 (de) | Neues, allgemein anwendbares antigen (psc-a) gegen pseudomonas aeruginosa, das als mittel zum schutz gegen pseudomonas aeruginosa-infektion wirkt | |
| DE943717C (de) | Verfahren zur Herstellung und Gewinnung eines Antibiotikums | |
| DE2004686A1 (de) | Antibiotica und Verfahren zu ihrer Herstellung | |
| CH423095A (de) | Verfahren zur Herstellung eines Tollwutimpfstoffes | |
| DE2755037C2 (de) | Pulverförmiges Mittel, enthaltend lebensfähige Zellen von Bifidobacterium | |
| DE1492243C3 (de) | Injizierbare Impfstoffe | |
| DE60214142T2 (de) | Flavonoidverbindung und herstellungsverfahren dafür | |
| DE3219814C2 (de) | Saccharose nicht fermentierender Pediococcus pentosaceus | |
| DE2342404C3 (de) | 3-(5,7-Dimethyl-2-hydroxy-4-oxo-6,8-decadienyI)-glutarimid sowie Verfahren zu dessen Herstellung | |
| DE2141901B2 (de) | Steriler Impfstoff, der abgetötete Organismen des genus Fusiformis nodosus enthält | |
| DE2029760A1 (de) | Immunologische Materialien und Verfahren zu ihrer Herstellung | |
| CH649709A5 (de) | Antitumor-praeparat und verfahren zu dessen herstellung. | |
| DE934429C (de) | Verfahren zur Erzeugung und Gewinnung eines Antibiotikums | |
| AT96830B (de) | Verfahren zur Herstellung eines Nährbodens für Influenzabazillen und zur Herstellung von Impfstoffen aus diesen. | |
| DE2239210B2 (de) | Verfahren zur Herstellung von a- Galactosidase, die eine starke a- Galactosidase-Aktivität und eine äußerst geringe Invertase-Aktivität aufweist, und deren Verwendung zur Zerlegung von Raffinose | |
| DE1717100C (de) | Verfahren zur Herstellung von Prapara ten hamolytischer Streptococcen zur unter stutzenden Behandlung von Carcinomerkrankun gen | |
| DE945949C (de) | Herstellung und Gewinnung eines Antibioticums | |
| DE2128626A1 (de) | Typhus-Vakzine und Verfahren zu deren Herstellung | |
| DE1041213B (de) | Verfahren zur Erzeugung von Antibiotika der Desmethyltetracyclinreihe |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased |